Contract analysis

I. Purpose and Executive Summary This memorandum is intended to provide a comprehensive and current inventory of all twelve (12) pending patent applications in the Optiwave Semiconductor Corp. ("OWS" or the "Company") prosecution docket maintained by Calderwood & Harkness LLP ("C&H"), to report the current prosecution status of each application on an application-by-application basis, to identify and rank by urgency a

II. Background A. Engagement History Calderwood & Harkness LLP was engaged by Optiwave Semiconductor Corp. to provide patent prosecution services pursuant to an engagement letter executed on February 10, 2022, countersigned by Marcus Whitfield in his capacity as General Counsel. The engagement was formally opened on February 14, 2022, and assigned C&H Matter No. 1014-00005. The C&H team was constituted as follows: •

III. Complete Docket Inventory — Application-by-Application Status This section provides a detailed status report for each of the twelve (12) pending patent applications in the OWS prosecution docket, organized by sub-family. For each application, we report the application type, filing date, jurisdiction, current prosecution status, next deadline, consequence of missing that deadline, and our assessment of the applic

IV. Critical Deadlines — Triage Summary (Ranked by Urgency) Priority Classification System To facilitate rapid assessment and decision-making, we have classified each pending deadline using a traffic-light risk system: • RED — Immediate action required. The deadline is imminent (fewer than 100 days remaining), and no or very limited extensions of time are available. Failure to act will result in irrevocable loss of p

1. Retrieve and review the incomplete draft Office Action response prepared by Christy Bauer through August 2023.

2. Update the claim amendment analysis in light of any intervening developments (including any newly published Pinnacle Optics patent applications or grants).

3. Finalize the proposed claim amendments emphasizing the tapered impedance-matching feature.

4. Complete the remarks and arguments section addressing the Examiner's § 103 obviousness rejections.

5. Determine whether a Request for Continued Examination ("RCE") is strategically advisable (e.g., if new claims or evidence are to be introduced that would not be appropriate in a response to the non-final Office Action).

6. Partner review by Catherine Bloom and finalization.

7. Quality control review, preparation of formal papers, and electronic filing with the USPTO. Estimated Cost: Approximately 40–55 attorney hours (primarily Christy Bauer at 30–40 hours and Catherine Bloom at 10–15 hours) at blended discounted rates, totaling approximately $22,000–$30,000 in C&H attorney fees. If an RCE is filed, the USPTO fee would be approximately $2,000 (small entity rate). If no RCE is needed, th

1. Analyze the Examiner's restriction rationale and determine whether traversal (contestation) is warranted.

2. Consult with OWS engineering personnel (Dr. Strickland and/or Dr. Chen) to determine which invention group is of highest commercial priority for initial prosecution in B1.

3. Prepare and file the election response, electing the chosen invention group and reserving the remaining groups for divisional prosecution.

4. If traversal is appropriate, prepare arguments explaining why the inventions are not patentably distinct. Estimated Cost: Approximately 8–12 attorney hours (primarily Christy Bauer and/or Peter Vassiliev), totaling approximately $4,500–$6,750 in C&H attorney fees. No additional USPTO fee is required for the restriction response itself. Following the election, the preparation and filing of the B2 divisional applica

1. Detailed analysis of the prior art references cited in the EESR.

2. Assessment of the EPO Examining Division's preliminary opinion on novelty (Art. 54 EPC) and inventive step (Art. 56 EPC).

3. Development of a response strategy, including identification of potential claim amendments to overcome the cited objections while maintaining commercially meaningful claim scope.

4. Drafting of amended claims and supporting arguments in coordination with Breitenfeld & Vogt.

5. Review and filing by Breitenfeld & Vogt in accordance with EPO procedural requirements. Estimated Cost: C&H attorney fees: approximately 20–30 hours at blended discounted rates (~$11,250–$16,875). Breitenfeld & Vogt foreign associate fees: approximately €3,500–€5,000 (~$3,800–$5,400 at ~$1.08/€). EPO examination fee: approximately €580 (~$626), if not already paid. Total estimated: approximately $15,000–$22,000. R

1. Identification and engagement of a qualified local patent associate (foreign associate) in each target jurisdiction.

2. Preparation of national-phase entry papers, including any required translations of the specification and claims into the local language.

3. Payment of national filing fees, designation fees, and any required examination fees.

4. Coordination of timely filing by the local associate on or before July 9, 2025. Estimated Cost: Costs vary significantly by jurisdiction and depend on the number of jurisdictions selected. As a general guideline, each national-phase entry typically costs approximately $5,000–$15,000 per jurisdiction, including translation fees, government filing fees, and local associate fees. Jurisdictions requiring extensive tra